First biosim infliximab in India debuts at 20% discount?
This article was originally published in Scrip
Executive Summary
The first biosimilar infliximab in India appears to have been launched at a discount of around 20% to the price of innovator Johnson &Johnson's Remicade (infliximab), according to some analysts tracking the development.